Research Update

Evolutec Group PLC
04 December 2006

Monday 4 December 2006



                               Evolutec Group plc
                         ('Evolutec' or 'the Company')

   Primary Endpoint Not Met in Phase IIb rEV131 Trial in Allergic Rhinitis

Evolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel
products for the treatment of allergic, inflammatory and autoimmune diseases,
announces that no significant differences were observed between rEV131 and
placebo in the Phase IIb trial in allergic rhinitis and the primary endpoint was
therefore not met.

Further clinical results with rEV131 from a second unrelated indication,
inflammation following cataract surgery, are anticipated early next year.  Once
these clinical results are received the Company will review its strategy for
rEV131.  This will be presented at the time of the preliminary results on 27
February 2007.

Mark Carnegie Brown, Chief Executive of Evolutec, said:

'This is tremendously disappointing for Evolutec and its shareholders.  We will
review our intended programmes with rEV131 once the post-cataract results are
received early next year and in the interim will continue to progress rEV576.'

Enquiries:

Evolutec                                                           0118 922 4480
Mark Carnegie Brown, Chief Executive Officer
Nicholas Badman, Chief Financial Officer
www.evolutec.co.uk

Financial Dynamics                                                 020 7831 3113
David Yates
Ben Brewerton


Notes for Editors:

About Evolutec

Evolutec, which is based in Reading, UK, is a clinical stage biopharmaceutical
company with a focus on allergy, inflammation and auto-immune diseases.

rEV576, the Company's second product development candidate is a complement
inhibitor which has demonstrated preclinical activity against the autoimmune
diseases myasthenia gravis and Guillain-Barre Syndrome, asthma and acute
myocardial infarction ('AMI') (heart attack).  Evolutec has established a
research collaboration with Case Western Reserve University, Cleveland, Ohio, to
undertake further preclinical work with rEV576 in myasthenia gravis. The Company
expects to commence clinical trials with rEV576 in 2007.

The rights to Evolutec's vaccine technology for animals are partnered with
Merial.  Merial is currently undertaking work in tick-borne diseases.

Evolutec is listed on the AIM market of the London Stock Exchange and develops
therapeutics originally isolated from the saliva of ticks.  The tick remains
undetected by its hosts, including humans, by injecting an array of molecules
into the skin that suppresses host immunity.  These stealth molecules have
undergone millions of years of natural evolution to select a promising efficacy,
potency and safety profile. Evolutec employs the tick's evolutionary stealth
technology to offer the potential of treating human diseases.


                      This information is provided by RNS
            The company news service from the London Stock Exchange